Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


Crinetics Pharmaceuticals(Nasdaq:CRNX), today announced that company management will participate in the following conferences in the month of December. Please see additional details below:


GlobeNewswire Inc | Nov 23, 2020 07:30AM EST

November 23, 2020

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals(Nasdaq:CRNX), today announced that company management will participate in the following conferences in the month of December. Please see additional details below:

Evercore ISI 3^rd Annual HealthCONx ConferenceDate: Thursday, December 3^rd, 2020Time: 1:00 - 1:45 pm ET in Track 1Panel: Easy Pills to Swallow: Oral Drugs for Large Endo MarketsPresenter: Dr. Scott Struthers,Founder& CEO Piper Sandler's 32^nd Annual Healthcare ConferenceDate: Tuesday - Thursday, December 1^st - 3^rd,2020Time: On demandPresenter: Dr. Scott Struthers,Founder& CEO, and Dr. Alan Krasner, Chief Medical Officer Pre-recorded fireside chats are available for the annual PiperWebcast: Sandler Healthcare Conference on the Events section on the Company?s website as well as on the Piper Sandler conference website.

About Crinetics PharmaceuticalsCrinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The companys lead product candidate, paltusotine (formerly CRN00808), is an oral selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 program in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with NETs in 2021. The company is also developing CRN04777, an oral nonpeptide somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushings disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the companys drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company. For more information, please visit https://crinetics.com.

Contacts:Marc WilsonChief Financial OfficerIR@crinetics.com (858) 450-6464

Investors / Media:Corey DavisLifeSci Advisorscdavis@lifesciadvisors.com (212) 915-2577

Aline SherwoodScienta Communicationsasherwood@scientapr.com(312) 238-8957







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC